Depo-Provera Lawsuit Overview
Depo-Provera (depot medroxyprogesterone acetate, or DMPA) is an injectable hormonal contraceptive manufactured by Pfizer that has been prescribed to millions of women in the United States since its FDA approval in 1992. Administered as an intramuscular injection every three months, Depo-Provera works by releasing a synthetic progestin hormone that prevents ovulation and pregnancy. While the medication has been widely used for birth control and the treatment of certain gynecological conditions, a growing body of scientific evidence suggests that prolonged Depo-Provera use may significantly increase the risk of developing meningioma, a type of brain tumor that arises from the meninges — the membranes surrounding the brain and spinal cord.
The connection between progestogen-based medications and meningioma risk has been the subject of increasing medical and legal scrutiny. In 2024, the French National Agency for Medicines and Health Products Safety (ANSM) issued updated warnings about the association between prolonged medroxyprogesterone acetate use and increased meningioma risk. Multiple peer-reviewed studies have documented a statistically significant elevated risk of meningioma among long-term Depo-Provera users, prompting researchers and regulators to call for updated labeling and greater patient awareness.
As a result of these findings, lawsuits have been filed against Pfizer alleging that the company knew or should have known about the increased meningioma risk associated with Depo-Provera and failed to adequately warn patients and healthcare providers. Plaintiffs allege that Pfizer prioritized profits over patient safety by not updating the drug's labeling to reflect the emerging scientific evidence. The Depo-Provera litigation is an evolving area of mass tort law, and new cases continue to be filed as more individuals learn about the potential connection between their Depo-Provera use and their meningioma diagnosis. If you received Depo-Provera injections and were diagnosed with a meningioma, you may have legal options to pursue compensation for your injuries.
The Scientific Link Between Depo-Provera and Meningiomas
The association between progestogen exposure and meningioma development is supported by a growing body of scientific and medical research. Meningiomas are the most common type of primary brain tumor, and the majority are classified as benign (Grade I). However, even benign meningiomas can cause significant health problems due to their location, including headaches, seizures, vision changes, cognitive impairment, and neurological deficits that may require surgical intervention.
A landmark study published in the British Medical Journal (BMJ) in 2024 analyzed health data from a large cohort of women and found that prolonged use of injectable medroxyprogesterone acetate (the active ingredient in Depo-Provera) was associated with a significantly increased risk of intracranial meningioma. The study reported that women who used DMPA for one year or more had an approximately 5.6-fold increased risk of developing a meningioma compared to women who had never used the medication. This finding was consistent with earlier research showing elevated meningioma risk among users of other progestogen-containing medications.
The biological mechanism underlying this association involves the interaction between synthetic progestins and progesterone receptors found on meningioma cells. Research has established that a substantial majority of meningiomas — estimated at 60% to 80% — express progesterone receptors. When synthetic progestins like medroxyprogesterone acetate bind to these receptors, they may stimulate tumor cell growth and proliferation. The sustained, high-dose progestin exposure provided by Depo-Provera injections, which maintain elevated hormone levels for months at a time, could create conditions favorable to meningioma development and growth.
Key scientific findings supporting the Depo-Provera and meningioma connection include:
- Dose-response relationship — Studies have shown that the risk of meningioma increases with longer duration of DMPA use, suggesting a dose-dependent relationship
- Progesterone receptor expression — The majority of meningiomas express progesterone receptors, providing a biological pathway for progestin-driven tumor growth
- Consistency across studies — Multiple independent studies conducted in different countries have reported similar associations between progestogen use and meningioma risk
- Tumor regression after discontinuation — Some case reports have documented meningioma shrinkage or stabilization after patients discontinued progestogen therapy, further supporting the causal link
Eligibility Criteria for a Depo-Provera Lawsuit
If you received Depo-Provera injections and were subsequently diagnosed with a meningioma or other brain tumor, you may be eligible to file a lawsuit seeking compensation for your injuries. While each case is evaluated on its own merits, the following general criteria are typically considered by attorneys reviewing potential Depo-Provera claims:
-
1
Documented Depo-Provera Use
You must be able to demonstrate that you received Depo-Provera (medroxyprogesterone acetate) injections. Medical records, pharmacy records, insurance claims, and healthcare provider records can all serve as evidence of your Depo-Provera use. Generally, claims involving longer-term use — typically one year or more of injections — may be considered stronger based on the scientific evidence showing a dose-response relationship. However, shorter-term use does not necessarily disqualify a claim.
-
2
Meningioma or Brain Tumor Diagnosis
You must have been diagnosed with a meningioma or related intracranial tumor. This includes benign (Grade I), atypical (Grade II), and malignant (Grade III) meningiomas, as well as multiple or recurrent meningiomas. Your diagnosis should be supported by medical imaging (MRI or CT scans), pathology reports from biopsy or surgical resection, and other clinical documentation. A confirmed histological diagnosis strengthens the claim.
-
3
Temporal Relationship Between Use and Diagnosis
Your meningioma diagnosis should have occurred during or after your period of Depo-Provera use. Meningiomas are typically slow-growing tumors, and the latency period between initial progestin exposure and tumor detection may span several years. A diagnosis that occurs years after Depo-Provera use does not preclude a claim, as these tumors may take considerable time to grow to a detectable size.
-
4
Statute of Limitations Compliance
Your claim must be filed within the applicable statute of limitations in your state. Because Depo-Provera meningioma cases involve latent injuries that may not be discovered until years after exposure, many states apply a "discovery rule" that starts the limitations period from the date you knew or reasonably should have known that your injury may be connected to Depo-Provera use. Given the relatively recent emergence of widespread public awareness about this connection, many individuals may still be within their filing window. Consulting with an attorney promptly is the best way to confirm your eligibility.
Family members and caregivers of individuals who have suffered serious complications or death related to Depo-Provera-linked meningiomas may also have standing to pursue legal claims, including wrongful death actions where applicable.
FDA Warnings and Regulatory Developments
The regulatory history of Depo-Provera and its relationship to meningioma risk is a critical component of the ongoing litigation. Plaintiffs allege that Pfizer failed to update Depo-Provera's labeling to reflect the growing body of scientific evidence linking the medication to increased meningioma risk, even as international regulatory agencies took action.
Depo-Provera received FDA approval in 1992 for use as a contraceptive, though it had been used in other countries for years prior. The drug's label has carried a black box warning since 2004 related to bone mineral density loss with prolonged use, but for many years, no comparable warning existed regarding meningioma risk. Critics argue that the absence of a meningioma warning on Depo-Provera's U.S. labeling left millions of patients and prescribing physicians without critical safety information needed to make informed medical decisions.
Key regulatory developments include:
- France (ANSM) — 2024: The French National Agency for Medicines and Health Products Safety issued updated recommendations warning about the increased risk of meningioma with prolonged use of injectable medroxyprogesterone acetate. The agency recommended that patients using DMPA be monitored for symptoms of meningioma and that the medication be contraindicated in patients with a history of meningioma.
- European Medicines Agency (EMA): European regulators have evaluated the meningioma risk associated with progestogen-containing medications and issued advisories for several products in this class.
- U.S. FDA: As of early 2026, the FDA has been reviewing the available evidence regarding meningioma risk associated with DMPA. Advocates and plaintiffs' attorneys have called on the FDA to require updated labeling for Depo-Provera to include a specific meningioma warning. Any labeling changes mandated by the FDA could have significant implications for the ongoing litigation.
The plaintiffs' core argument in the Depo-Provera litigation centers on the principle of failure to warn. Under product liability law, pharmaceutical manufacturers have a duty to provide adequate warnings about known or reasonably foreseeable risks associated with their products. Plaintiffs allege that Pfizer was aware of the scientific evidence linking medroxyprogesterone acetate to meningioma risk and had a duty to update the drug's warnings to inform patients and their doctors. The failure to provide this warning, plaintiffs argue, deprived patients of the ability to make fully informed decisions about their healthcare and exposed them to unnecessary risk of serious brain tumors.
How to File a Depo-Provera Lawsuit
If you believe you may have a Depo-Provera meningioma claim, understanding the legal process may help you feel more prepared to take the next steps. Below is a general overview of the stages typically involved in pursuing a Depo-Provera brain tumor lawsuit:
-
1
Free Case Review
The first step is a free, confidential consultation with an attorney experienced in pharmaceutical litigation. During this review, the attorney will evaluate your Depo-Provera injection history, meningioma diagnosis, treatment records, and other relevant details to determine whether you may have a viable claim. Most pharmaceutical injury attorneys work on a contingency fee basis, meaning there are no upfront costs to you, and fees are only collected if a recovery is obtained on your behalf.
-
2
Gathering Medical Evidence
Your legal team will work to collect comprehensive documentation supporting your claim, including medical records showing your Depo-Provera prescription and injection history, neuroimaging studies (MRI, CT scans), surgical and pathology reports documenting your meningioma, and records of ongoing treatment and rehabilitation. Expert medical opinions may also be obtained to establish the causal connection between your Depo-Provera use and your meningioma.
-
3
Filing the Lawsuit
If your attorney determines you have a qualifying claim, they will prepare and file a legal complaint against Pfizer and potentially other defendants. As the Depo-Provera litigation continues to develop, cases may be consolidated into a multidistrict litigation (MDL) for more efficient pretrial proceedings. Your attorney will advise you on the most appropriate court and legal strategy for your particular case.
-
4
Litigation, Settlement, or Trial
After filing, the case will proceed through discovery, where both sides exchange evidence and information. This phase may include depositions, expert witness reports, and document production. Many pharmaceutical injury cases are ultimately resolved through settlement negotiations, though some may go to trial if a satisfactory agreement cannot be reached. Because the Depo-Provera litigation is still in its earlier stages, the timeline for resolution may vary. Early bellwether trials or settlement discussions could set important precedents for the valuation and resolution of these claims.
Types of Compensation in Depo-Provera Meningioma Cases
Individuals who file a Depo-Provera lawsuit may be able to recover several categories of damages related to their meningioma diagnosis and treatment. Meningiomas, even when classified as benign, can require serious medical intervention including brain surgery, radiation, and long-term monitoring, leading to substantial financial and personal costs. While no specific outcome is guaranteed, the following types of compensation are commonly pursued in Depo-Provera brain tumor cases:
- Medical Expenses — Compensation for all past and future medical costs related to your meningioma, including neurosurgery, radiation therapy, diagnostic imaging (MRI, CT scans), hospital stays, follow-up appointments, prescription medications, physical therapy, speech therapy, occupational therapy, and long-term monitoring. Brain tumor treatment can be exceptionally expensive, and a successful claim may help offset these costs.
- Lost Wages and Earning Capacity — Recovery for income lost due to time away from work for surgery, treatment, and recovery, as well as diminished future earning capacity if your meningioma or its treatment has caused cognitive, neurological, or physical impairments that affect your ability to work.
- Pain and Suffering — Damages for the physical pain, emotional distress, anxiety, fear, depression, and reduced quality of life resulting from a brain tumor diagnosis and the surgeries, treatments, and lifestyle changes it may require. The psychological impact of a brain tumor diagnosis can be profound, and these non-economic damages often constitute a significant portion of total compensation.
- Disability and Impairment — Compensation for permanent neurological deficits, cognitive impairment, vision loss, hearing loss, mobility issues, or other disabilities resulting from the meningioma itself or from the surgical procedures required to remove it.
- Loss of Consortium — Damages for the impact of your condition on your relationships with your spouse or partner, including loss of companionship, intimacy, and support.
- Punitive Damages — If the court finds that Pfizer's failure to warn about meningioma risk was willful, reckless, or constituted gross negligence, punitive damages may be awarded to punish the company and deter similar conduct by pharmaceutical manufacturers in the future.
Why You Should Take Action Now
The Depo-Provera meningioma litigation is still in its early stages, and there are compelling reasons to evaluate your legal options sooner rather than later if you believe you may have a qualifying claim.
Emerging Litigation — Early Filing Advantages: Because the Depo-Provera brain tumor litigation is still developing, individuals who file claims early may benefit from being included in initial case groupings, bellwether trial selections, and early settlement discussions. Mass tort litigations often establish precedent through early cases that can shape the outcome and valuation of subsequent claims. Being part of the early wave of litigation may position your case favorably as the legal landscape evolves.
Statute of Limitations Considerations: Although the discovery rule may extend the filing window for many Depo-Provera meningioma claims, statutes of limitations still apply and vary by state. Once you become aware — or reasonably should have become aware — of the potential connection between Depo-Provera and your meningioma, the clock may begin running on your filing deadline. As media coverage and public awareness of this issue continue to grow, courts may become less receptive to arguments that plaintiffs were unaware of the risk. Acting promptly protects your rights and ensures your claim is filed within the required timeframe.
Preserving Medical and Pharmacy Records: Key evidence in a Depo-Provera claim includes your injection history, pharmacy records, and medical records documenting your meningioma diagnosis and treatment. Over time, these records may become more difficult to obtain, particularly if healthcare providers change record retention systems or if the records age beyond mandatory retention periods. Initiating a legal claim early helps ensure that your legal team can secure and preserve all necessary evidence.
No Financial Risk: Like most mass tort pharmaceutical cases, Depo-Provera meningioma lawsuits are typically handled on a contingency fee basis. You pay no upfront costs, and attorney fees are only collected if compensation is recovered on your behalf. A free case review can help you understand whether you have a viable claim and what options may be available to you without any financial obligation.